Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01416428 · ClinicalTrials.gov registry record · Phase 1
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 210
- Enrollment target
NCT01416428 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 210 participants.
The verdict
NCT01416428, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 210 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose (MTD), activity, and safety of oprozomib in patients with hematologic malignancies.
Interventions
- DRUG oprozomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2011-10-15 |
| Est. Completion | 2019-08-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01416428
The ClinicalTrials.gov registry entry for NCT01416428 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which oprozomib is the first listed.
NCT01416428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01416428 about?
NCT01416428 is a clinical study titled "Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies". The purpose of this study is to determine the maximum tolerated dose (MTD), activity, and safety of oprozomib in patients with hematologic malignancies.
What is the current status of trial NCT01416428?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 210 participants. The study started on 2011-10-15. Estimated completion is 2019-08-12.
What interventions are being tested in trial NCT01416428?
The interventions under investigation include: oprozomib (DRUG).
Who is sponsoring clinical trial NCT01416428?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.